VIR
Vir Biotechnology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.39
−0.57%Aug 13, 2026, 00:00 UTC
Olema Pharmaceuticals appointed Jason O'Byrne as Chief Financial Officer, principal financial officer and principal accounting officer, effective as of the announcement date.
Aug 6, 2026, 01:36 UTC
Vir Biotechnology, Inc. reported Q2 2026 earnings of $0.47 per share, missing the Zacks Consensus Estimate of $0.83 per share, compared to a loss of $0.80 per share a year ago.
Jul 24, 2026, 12:30 UTC
Vir Biotechnology announced that Brent Sabatini was appointed Interim Principal Financial Officer, effective July 23, and that Jason O'Byrne is leaving the company to pursue another opportunity, remaining through August 3 for a smooth transition.
Source: